An Introduction to Renal Cancer
The treatment landscape for renal cell carcinoma (RCC) has been transformed in recent years. Immune checkpoint inhibitors (ICIs) are becoming the first-line treatment for metastatic disease; and combined administrations of two ICIs or one tyrosine kinase inhibitor plus one ICI have greatly improved survival of clear cell RCC, the most common RCC subtype. Improved understanding of RCC pathology, the microenvironment and the immune system is likely to contribute to the development of new treatment.
Browse the content below where leading experts, discuss the latest data in video interviews and short articles from our conference hub and browse the selection of peer-reviewed articles from our journal portfolio. If you’re looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Renal Cancer Content
The Role of High-Dose IL-2 in mRCC today
Watch leading experts discuss recent developments in checkpoint inhibitor therapy to treat mRCC,5,6 and the findings from a recent analysis of the PROCLAIMSM registry.
- Understand the importance of clinical risk factors in the treatment and management of mRCC and be aware of the current NCCN recommendations.
- Appreciate the clinical benefits and safety profile, including risks, of high-dose interleukin-2 therapy and how these may guide treatment decisions dependent on clinical risk factors.
- Demonstrate an awareness of the results of the CheckMate 214 study, showing differing survival and clinical response outcomes in patients with mRCC receiving checkpoint inhibitor therapy dependent on disease risk category.
- Understand the latest results from the PROCLAIMSM database, showing consistent survival benefits with high-dose interleukin-2 therapy across favorable, intermediate and poor-risk mRCC patients.
- Appreciate how these recent findings might alter the treatment paradigm for mRCC.
Yann-Alexandre Vano, ESMO 2020 – Nivolumab and Ipilimumab or VEGFR Tyrosine Kinase Inhibitor in Naive Metastatic Kidney Cancer: The BIONIKK Trial
Dr Yann-Alexandre Vano joins touchONCOLOGY to discuss the role of personalization of treatment in kidney cancer, and the major findings from the BIONIKK trial investigating nivolumab and ipilimumab as a first-line therapy for patients with kidney cancer. The late-breaking abstract ‘Results from the phase 2 BIOmarker driven trial with Nivolumab (N) and Ipilimumab or VEGFR […]
Lorenza Rimassa, ESMO 2019 – COSMIC-312 study in hepatocellular carcinoma
We joined Lorenza Rimassa (Humanitas Research Hospital-IRCCS) at ESMO 2019 to discuss the Phase III COSMIC-312 study (NCT03755791) of cabozantinib plus atezolizumab versus sorafenib in patients with advanced hepatocellular carcinoma. Questions 1. What are the limitations of current first-line treatment strategies for advanced hepatocellular carcinoma? (0:05) 2. What is the rationale for combining cabozantinib with […]
James Brugarolas, ASCO 2019 – Advances in sarcomatoid RCC
At the ASCO 2019 annual meeting, James Brugarolas discusses sarcomatoid renal cell carcinoma, the current challenges and the advances that are defining a new treatment paradigm. Questions 1. What is sarcomatoid renal cell carcinoma (RCC) and what is its prognosis? (0:04) 2. What are the major treatment challenges in sarcomatoid RCC? (0:54) 3. Why is […]
Hamid Emamekhoo, ASCO 2019 – CheckMate 920 study
At the ASCO 2019 annual meeting, Hamid Emamekhoo discusses the efficacy and safety of the combination of nivolumab plus ipilimumab in patients with symptomatic melanoma brain metastases (CheckMate 204) and how these findings will likely impact the management of the disease. Questions 1. What are the limitations of current treatment options for patients with metastatic […]
Personalized Therapy in Advanced Renal Cancer
Oncology & Hematology Review. 2018;14(2):74–5 DOI: https://doi.org/10.17925/OHR.2018.14.2.74
In recent years, personalized therapies have transformed the management of many advanced malignancies. However, despite advances in targeted therapy and immunotherapy that have expanded the treatment options for patients with metastatic kidney cancer, we are unable to predict which patients are most likely to respond to individual treatments.1 With a number of highly effective […]
First-line Treatment Options for Renal Cell Carcinoma
Dr Ulka Vaishampayan, from Karmanos Cancer Institute, Wayne State University, MI, USA, discusses first-line treatment options for renal cell carcinoma, including the promising findings from the PROCLAIM registry, which suggest that high dose interleukin-2 is safe and effective before targeted therapy and immune checkpoint blockade.
Giuseppe Procopio, ASCO 2018 – Sorafenib in renal cell carcinoma – the RESORT trial
Giuseppe Procopio from Fondazione IRCCS Instituto Nazionale dei Tumori in Milan, Italy talks to us about the RESORT trial and limitations of using sorafenib in patients with metastatic renal cell carcinoma after radical resection of metastases. 1. What is the rationale for investigating radical resection of metastases followed by sorafenib in advanced renal cell carcinoma? […]
Arnaud Méjean, ASCO 2018 – Cytoreductive nephrectomy and the CARMENA trial
Arnaud Méjean from the HEGP, Université Paris Descartes and ADHP in Paris, France, discusses the place of cytoreductive nephrectomy in the management of patients with metastatic renal cell carcinoma, and how this approach may change based on the results of the CARMENA trial. 1. What is the current role of cytoreductive nephrectomy in the management […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!